期刊
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
卷 170, 期 -, 页码 -出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2022.103597
关键词
Colorectal cancer; Immunotherapy; MMR; MMR deficiency; MSI; PD-1; PD-L1; Solid tumors; Tumor-agnostic therapy
Alterations in short-repetitive DNA sequences, known as microsatellite instability (MSI), can reflect deficiencies in mismatch repair (MMR) system. The dMMR/MSI status can better predict the response to immune checkpoint inhibitors (ICIs) in patients with solid tumors. Tissue-agnostic evaluation of MSI-H/dMMR may become a standardized approach for selecting patient subgroups who may benefit from immunotherapy.
Alterations in short-repetitive DNA sequences, known as microsatellite instability (MSI), can reflect deficiencies in Mismatch Repair (MMR) system which represents a major player in DNA integrity maintenance. The incidence of MSI-H/dMMR has been shown to be variable depending on the tumor type. Several studies confirmed that dMMR/MSI status, although less frequent than PD-L1 expression, may better predict response to immunecheckpoint inhibitors (ICIs) in patients with solid tumors. In October 2016, the FDA granted pembrolizumab as breakthrough therapy for the treatment of non-CRC, MSI-H/dMMR tumors, providing, for the first time, a tumor-agnostic indication. In the next future, the tissue-agnostic evaluation of MSI-H/dMMR could become the common denominator for the immunotherapy treatment of patients with different advanced solid tumors, in order to select patient subgroups which may benefit from this therapy. In this Review we provided an overview of the main clinical studies describing the association between MSI-H/dMMR tumors and immunotherapy response.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据